Accessibility Menu
Lensar logo

Lensar(NASDAQ) LNSR

Current Price$5.72
Market Cap$69.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-36%
5 Year-23%
1 Year-56%
1 Month+0%
Lensar last closing stock price
MetricPriceDate
Last closeUSD 5.752026-07-20
Lensar stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.2%USD 5.822026-07-13
1 month+0.17%USD 5.742026-06-18
3 month+7.48%USD 5.352026-04-21
Year to date-50.56%USD 11.632025-12-31
1 year-56.11%USD 13.102025-07-18
3 year+68.13%USD 3.422023-07-21
5 year-23.33%USD 7.502021-07-21
Since inception-36.11%USD 9.002020-10-02

Lensar Financials at a Glance

Market Cap

$69.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$57.70M

Net Income (TTM)

$29.40M

EPS (TTM)

-$0.57

P/E Ratio

-10.01

Dividend

$0.00

Beta (Volatility)

0.46 (Low)

Price

$5.72

Volume

33

Open

$5.74

Previous Close

$5.72

Daily Range

$5.72 - $5.74

52-Week Range

$5.06 - $13.43

Estimated Earnings Date

Aug 6, 2026

LNSR News

Foolcom-Featured.png

Lensar (LNSR) Q2 Revenue Rises 10%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lensar

LENSAR makes laser systems that help eye surgeons treat cataracts and astigmatism. Its technology aims to make eye surgery faster and more precise for doctors and patients. Hospitals and clinics use these systems to improve vision outcomes and streamline procedures.

Laser Focus: Products and Services

  • LENSAR Laser System (LLS): Main laser platform for cataract surgery; used by eye surgeons in hospitals and clinics.
  • ALLY Robotic Cataract Laser System: Compact robotic laser for cataract surgery; integrates imaging and planning; targets high-volume surgical centers.
  • Consumables (PID kits, procedure licenses): Single-use items and software needed for each surgery; 79% of 2025 revenue (with service and lease).
  • Service and Maintenance: Extended warranties, repairs, and training for installed systems; 17% growth in 2025 service revenue.
  • Leasing Options: Flexible system leasing for clinics; lease revenue was 12% of total in 2025.

Growth Spurts: Expansion and Strategy

  • Launched ALLY Robotic Cataract Laser System beginning in August 2022, expanding product line.
  • Secured EU MDR certification in August 2024, enabling European market entry.
  • Gained regulatory clearances in India, Taiwan, and South Korea by 2025.
  • Expanded U.S. direct sales force and international distributor network in 2025.
  • Terminated merger with Alcon in March 2026, retaining $10 million deposit.

What Makes LENSAR Stand Out

LENSAR operates in 17 countries, selling directly in the U.S. and through distributors abroad. Its systems use proprietary imaging and artificial intelligence to help surgeons plan and perform eye surgeries more efficiently. The company holds over 300 patents and focuses on recurring revenue from consumables and services.

Five Things You Need to Know

  • 2025 revenue was $58.4 million, up 9% from 2024.
  • Recurring revenue (consumables, service, lease) made up 79% in 2025.
  • Operating loss was $(24.6) million in 2025, up from $(10.7) million in 2024.
  • Installed base reached 435 systems in 17 countries by end of 2025.
  • Procedure volume grew 21.5% to 206,014 in 2025.

Bottom Line

LENSAR has grown by expanding its product line and global reach, focusing on recurring revenue. The company faces ongoing losses but continues to invest in technology and market presence.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

150

CEO

Nicholas T. Curtis

Website

www.lensar.com

Headquarters

Orlando, FL 32826, US

LNSR Financials

Key Financial Metrics (TTM)

Gross Margin

45.32%

Operating Margin

-28.68%

Net Income Margin

50.94%

Return on Equity

-514.92%

Return on Capital

N/A

Return on Assets

44.39%

Earnings Yield

-9.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$69.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.10M

Volume

33

Avg. Volume

73.33K

Financials (TTM)

Gross Profit

$26.15M

Operating Income

-$16.55M

EBITDA

$33.96M

Operating Cash Flow

-$12.16M

Capital Expenditure

-$77.00K

Free Cash Flow

-$12.24M

Cash & ST Invst.

$13.50M

Total Debt

$2.57M

Lensar Performance Analysis

Lensar annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 35,358,0002.6%
20232023-12-31USD 42,164,00019.2%
20242024-12-31USD 53,494,00026.9%
20252025-12-31USD 58,435,0009.2%
Lensar sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.6%
Q32025-09-302.7%
Q42025-12-3111.9%
Q12026-03-31-16.2%
Lensar annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.96-6.3%
20232023-12-31USD -1.31-33.1%
20242024-12-31USD -2.73108.0%
20252025-12-31USD -2.875.1%
Lensar sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3093.5%
Q32025-09-30-106.7%
Q42025-12-3161.3%
Q12026-03-31101.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$13.43M

-5.2%

Gross Profit

$6.38M

-10.4%

Gross Margin

47.53%

N/A

Market Cap

$69.60MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$464.00K

N/A

Employees

150

N/A

Net Income

$36.33M

+232.9%

EBITDA

$37.47M

+242.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.50M

-46.5%

Total Debt

$2.57M

+4.1%

Accounts Receivable

$5.18M

-28.4%

Inventory

$23.10M

+50.7%

Long Term Debt

$1.79M

-8.5%

Short Term Debt

$785.00K

+51.8%

Return on Assets

44.39%

N/A

Return on Invested Capital

-34.18%

N/A

Free Cash Flow

-$4.27M

+38.5%

Operating Cash Flow

-$4.27M

+38.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRDFCardiff Oncology, Inc.
$0.83-1.01%
RPIDRapid Micro Biosystems, Inc.
$2.07-0.24%
OWLTOwlet, Inc.
$5.52-2.13%
ARAYAccuray Incorporated
$0.25+0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
MARAMara Holdings
$12.32+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.32+0.06%
TET1 Energy Inc.
$6.14+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.27-0.06%

Questions About LNSR

What is the current price of Lensar?

Lensar is trading at $5.72 per share.

What is the 52-week range for Lensar?

Over the past 52 weeks, Lensar has traded between $5.06 and $13.43.

How much debt does Lensar have?

As of the most recent reporting period, Lensar reported total debt of $2.57M.

How much cash does Lensar have on hand?

Lensar reported $12.49M in cash and cash equivalents in its most recent financial results.

What is Lensar’s dividend yield?

Lensar does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services